Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings.
O'Brien D, Spelman T, Greig J, McMahon J, Ssonko C, Casas E, Mesic A, Du Cros P, Ford N
Progress in Medicine: Experts Take Stock.
PLOS Medicine Editors, Beck A, Birney E, Graeber M, Tumwine J, Hay P, Ahn HS, Patel A, du Cros P, von Seidlein L, Wareham N, Low N
Generating Evidence to Improve the Response to Neglected Diseases: How Operational Research in a Médecins Sans Frontières Buruli Ulcer Treatment Programme Informed International Management Guidance.
O'Brien DP, Ford N, Vitoria M, Asiedu K, Calmy A, Du Cros P, Comte E, Christinet V
Challenges and solutions to implementing drug-resistant tuberculosis programmes for children in Central Asia.
du Cros P, Swaminathan A, Bobokhojaev OI, Sharifovna ZD, Martin C, Herboczek K, Höhn C, Seddon JA
Reply: How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?
Bastard M, Bonnet M, du Cros P, Khamraev AK, Hayrapetyan A, Kimenye K, Khurkhumal S, Dlamini T, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F
Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis.
Rao VB, Johari N, du Cros P, Messina J, Ford N, Cooke GS